Canine atopic dermatitis is a chronic, pruritic inflammatory skin disease affecting up to 10% of dogs, with modern targeted therapies transforming quality of life outcomes for affected animals.
Canine atopic dermatitis represents a significant chronic welfare burden because uncontrolled pruritus causes constant distress — dogs scratch, bite, and rub affected areas compulsively, disrupting sleep, social interaction, and enjoyment of activities. Before modern targeted therapies, management relied heavily on corticosteroids with their associated side effects. The advent of cytokine inhibitors has transformed the welfare outlook for atopic dogs, providing rapid and sustained itch control with minimal side effects when used appropriately. Owners must understand that CAD is typically lifelong and requires sustained management rather than intermittent treatment — gaps in management cause welfare suffering that accumulates over time. Welfare-centered management integrates skin barrier support, allergen avoidance where feasible, immunotherapy, and pharmacological itch control.